RxDoctor Payments Data

Mark Kassels, MD

Ophthalmology · Sheffield, ALNPI 1437114055

Payments from drug & device makers

$2,034in general payments, 2019–2025

Across 59 payments — averaging $34.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson Surgical Vision, Inc.$1K
  • Alcon$445
  • AbbVie$79
  • Oyster Point Pharma, Inc.$74
  • Aerie Pharmaceuticals, Inc.$72
  • Sun Pharmaceutical Industries Inc.$39
  • plus $150 from 6 others

What the payments were for

  • Food & beverage$2,034100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,034 in reported general payments places this provider in the 50th percentile of 197 ophthalmology providers in Alabama.

See all ophthalmology providers in Alabama

Medicare billing

Part B allowed, 2024
$284,597
Medicare patients
805
Services billed
2,555

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RocklatanNetarsudil Mesylat/Latanoprost168$67,313
LumiganBimatoprost133$47,201
RhopressaNetarsudil Mesylate117$46,154
RestasisCyclosporine50$37,611
XdemvyLotilaner13$23,328
Cyclosporine39$20,873
Latanoprost1,393$16,642
Travoprost92$14,886
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol44$11,540
Brimonidine Tartrate210$9,379
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat410$8,987
VyzultaLatanoprostene Bunod23$8,725
Timolol Maleate509$6,788
CombiganBrimonidine Tartrate/Timolol16$5,936
SimbrinzaBrinzolamide/Brimonidine Tart27$5,762

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$72$113,467285 claims
AbbVieLumigan, Restasis, Combigan, Alphagan P$79$95,267213 claims
AlconSimbrinza$445$5,76227 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$23$1,85314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 197 ophthalmology providers in Alabama.

Other ophthalmology in Sheffield

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →